Bleeding Reduction in Grade II-III Haemorrhoids Through Embolization Treatment

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorCardiovascular and Interventional Radiological Society of Europe

About this trial

BRIGHT is a Europe-wide study that will follow up to 250 adults with bleeding symptoms from haemmorhoids (Grade II-III categories). It aims to understand how well a minimally invasive procedure called haemorrhoid artery embolization (HAE) works in everyday clinical practice, which is a technique that blocks the blood vessels feeding the haemorrhoids. As this technique does not require major surgery, HAE offers several benefits such as less trauma, quicker recovery, and the use of only local anaesthesia.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adult patients presenting bleeding Grade II-III haemorrhoids with French bleeding score ≥3 planned to be treated with HAE using embolization coils;

Patients competent and willing to give written informed consent.

Disqualifiers

Minors and other vulnerable populations who may not be able to give informed consent freely or for whom participation is not essential to the study (incapacitated and unconscious individuals, persons deprived of liberty, pregnant and breastfeeding women, etc.);

Patients receiving HAE using a combination of coils and particles, particles only, or any other embolic agents;

Patients who have had previous surgical haemorrhoidectomy at any time or other treatments for haemorrhoids within 1 year before the planned HAE;

Patients with known perianal sepsis, inflammatory bowel disease, peri-anal fistula, colorectal malignancy or pre-existing sphincter injury resulting in incontinence;

Trial population

Adult patients with bleeding grade II-III haemorrhoids (French Bleeding Score ≥3) planned to be treated with HAE coil-only embolization who fit the eligibility criteria

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Haemorrhoid artery embolizsation (HAE)

    Procedure/Surgery

    Haemorrhoid artery embolization (HAE) is a minimally invasive procedure used to treat symptomatic haemorrhoids by reducing their blood supply. Under imaging guidance, typically fluoroscopy, a catheter is inserted through a small puncture in the groin or wrist and guided into the arteries that supply the haemorrhoidal tissue, known as the superior rectal arteries. Once the target vessels are identified, embolization coils-tiny metal coils designed to block blood flow-are placed inside these arteries. The coils create a controlled blockage, decreasing blood flow to the haemorrhoids, which helps shrink the swollen tissue and reduce bleeding. HAE is usually performed as an day-case procedure under local anaesthesia with mild sedation, and tends to result in less pain, quicker recovery, and lower complication rates compared to surgical approaches.

Treatment groups

250 Participants
are divided into 1 treatment group
Group A: Adult patients with bleeding grade II-III haemorrhoids1 intervention

Trial outcomes

Primary outcomes

1

Haemorrhoidal bleeding

Evaluated using the French Bleeding Score.

Time frame
12 months

Secondary outcomes

1

Haemorrhoidal bleeding

Evaluation of haemorrhoidal bleeding at time points listed below compared to baseline using the French Bleeding Score.

Time frame
1, 3 and 24 months
2

Patient-reported Pain using the Visual Analogue Scale

The 10 cm Visual Analogue Scale (VAS) is a patient-reported outcome measure used to assess the intensity of a symptom such as pain, discomfort, or bleeding. It consists of a straight, 10-centimeter horizontal line with two anchored endpoints: 0 cm = no symptom, and 10 cm = worst imaginable symptom. Participants mark a point on the line that best represents the severity of their symptom at the time of assessment. This will be measured at 1 day, 1- and 3-months after the treatment.

Time frame
1 day, 1- and 3-months post treatment, compared to baseline
3

Patient-reported Pain measured by Analgesic intake

Analgesic intake refers to the use of any pain-relief medication taken to manage haemorrhoid-related discomfort after HAE. This includes over-the-counter or prescribed agents such as acetaminophen/paracetamol or NSAIDs. Participants will be recorded as having taken analgesics if they use any pain medication for haemorrhoid symptoms during the specified time frame.

Time frame
1 day, 1- and 3-months post treatment
4

Frequency and severity of procedural complications and other adverse events

The severity of complications and procedure-related adverse events will be graded according to the Clavian Dindo classification system.

Time frame
Within 3 months after the HAE procedure

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Cardiovascular and Interventional Radiological Society of Europe

Lead sponsor

Medtronic

Collaborator

Cook Group Incorporated

Collaborator

This trial is not recruiting at the moment. You can still explore other options: